Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sailing A: Peginterferon alfa-2b plus nucleos(t)ide analogues vs nucleos(t)ide analogue monotherapy in HBeAg-positive chronic hepatitis B
ChiCTR2400082960Phase 4Recruiting
- Sponsor
- The First People's Hospital of Yunnan Province
- Start
- Apr 2024
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b, entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by The First People's Hospital of Yunnan Province. Primary endpoint: HBeAg seroconversion rate. Started Apr 2024; status: recruiting.
02
Drugs
peginterferon alfa-2bentecavirtenofovir disoproxil fumaratetenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2400082960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082960.